Jim Beach
Directeur des opérations chez Camargo Pharmaceutical Services LLC
Profil
Jim Beach has worked as Head of Operations at Bexion Pharmaceuticals, Inc. and as Chief Operating Officer at Camargo Pharmaceutical Services LLC from 2013 to present.
Postes actifs de Jim Beach
| Sociétés | Poste | Début |
|---|---|---|
Camargo Pharmaceutical Services LLC
 Camargo Pharmaceutical Services LLC Miscellaneous Commercial ServicesCommercial Services Camargo Pharmaceutical Services LLC provides contract drug development, formulation, testing and regulatory consulting services. The company was founded by Kenneth V. Phelps and Ruth E. Stevens in 2003 and is headquartered in Cincinnati, OH. | Directeur des opérations | 20/11/2013 |
Bexion Pharmaceuticals, Inc.
 Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | Directeur des opérations | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Camargo Pharmaceutical Services LLC
Camargo Pharmaceutical Services LLC Miscellaneous Commercial ServicesCommercial Services Camargo Pharmaceutical Services LLC provides contract drug development, formulation, testing and regulatory consulting services. The company was founded by Kenneth V. Phelps and Ruth E. Stevens in 2003 and is headquartered in Cincinnati, OH. | Commercial Services |
Bexion Pharmaceuticals, Inc.
Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | Commercial Services |